Radius Pharmaceutical, Inc. (RDUS)

Oncology Corporate Profile

Stock Performance

37.3800
-0.0300

HQ Location

950 Winter St.
Waltham, MA 2451

Company Description

Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for osteoporosis and the investigational drug RAD1901 for hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases.

Website: http://www.radiuspharm.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
RAD1901SERM modulatorBreast cancerI

View additional information on product candidates here »

Source


http://www.radiuspharm.com/

Recent News Headlines

Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC

3/10/2017 02:01 pm

[GlobeNewswire] - WALTHAM, Mass., March 10, 2017-- Radius Health, Inc., a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine ...

Radius Health to Present at Cowen and Company 37th Annual Health Care Conference

2/28/2017 12:00 pm

[GlobeNewswire] - WALTHAM, Mass., Feb. 28, 2017-- Radius Health, Inc., a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, ...

Radius Health Reports Fourth Quarter and Full Year 2016 Financial and Operating Results

2/23/2017 09:00 pm

[GlobeNewswire] - US FDA PDUFA for abaloparatide-SC is March 30, 2017. Build out of Commercial Organization to be completed in 1 Q 2017. 24- month ACTIVExtend trial has concluded, Radius to report top-line results in 2 ...

Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis

2/1/2017 01:02 pm

[GlobeNewswire] - –Results from interim analysis of the ACTIVExtend study of postmenopausal women with osteoporosis treated for 18 months with investigational drug abaloparatide-SC in the ACTIVE trial who were transitioned ...

Radius Health to Announce Fourth Quarter and Full Year 2016 Financial Results, Host Conference Call and Live Webcast on February 23, 2017

1/31/2017 12:00 pm

[GlobeNewswire] - WALTHAM, Mass., Jan. 31, 2017-- Radius Health announced today that it will release its fourth quarter and full year 2016 financial results on Thursday, February 23, 2017.. In connection with the earnings ...

Radius Health to Present at the 35th Annual J.P. Morgan Healthcare Conference

1/6/2017 01:04 pm

[GlobeNewswire] - WALTHAM, Mass., Jan. 06, 2017-- Radius Health, Inc., a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, ...